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Abstract
Studies using traditional treatment strategies for mild traumatic brain injury (TBI) have produced 
limited clinical success. Interest in treatment for mild TBI is at an all time high due to its 
association with the development of chronic traumatic encephalopathy and other 
neurodegenerative diseases, yet therapeutic options remain limited. Traditional pharmaceutical 
interventions have failed to transition to the clinic for the treatment of mild TBI. As such, many 
pre-clinical studies are now implementing non-pharmaceutical therapies for TBI. These studies 
have demonstrated promise, particularly those that modulate secondary injury cascades activated 
after injury. Because no TBI therapy has been discovered for mild injury, researchers now look to 
pharmaceutical supplementation in an attempt to foster success in human clinical trials. Non-
traditional therapies, such as acupuncture and even music therapy are being considered to combat 
the neuropsychiatric symptoms of TBI. In this review, we highlight alternative approaches that 
have been studied in clinical and pre-clinical studies of TBI, and other related forms of neural 
injury. The purpose of this review is to stimulate further investigation into novel and innovative 
approaches that can be used to treat the mechanisms and symptoms of mild TBI.
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Introduction
Traumatic brain injury (TBI) continues to be a major cause of morbidity and mortality 
worldwide. Recently, mild repetitive TBI was found to be a possible contributor to the 
development of neurodegenerative diseases.1 In this review, we focus on the secondary 
injury effects of mild TBI, and the various effective supplement and alternative strategies 
being investigated in both pre-clinical and clinical studies. Preventing primary injury, such 
as the acceleration/deceleration from collision or skull impact, can only be targeted through 
patient education or improved protective equipment. As such, TBI research has focused on 
the treatment of secondary injury effects, which we will focus on in this review. Secondary 
injury cascades following mild TBI have been linked to the development of progressive 
degeneration and disease burden.2 Important cascades include oxidative stress, endoplasmic 
reticulum (ER) stress, mitochondrial dysfunction, and neuroinflammation. These cascades 
are thought to contribute to the development of seizures, sleep disruption, depression, 
impulsivity, and cognitive decline, which can manifest months to years after initial injury.3 
To date, no effective treatments are available to target these secondary injury cascades. A 
recent interest has focused on the benefits of supplements, nutrition, and alternative 
therapies for the treatment of mild TBI and subsequent symptoms. Supplements have shown 
beneficial outcomes when administered in pre-clinical models of TBI,4 and clinical case 
series have also alluded to the importance of supplements and nutrition for recovery 
following mild TBI in patients.5 Furthermore, alternative therapies such as music therapy, 
acupressure, and acupuncture have been used to treat symptoms associated with mild TBI. 
In this review, we provide an overview of both acute and chronic mild TBI-related 
symptoms, discuss the secondary mechanisms associated with mild TBI, and highlight 
supplements, nutritional interventions, and alternative therapies that warrant further 
investigation.
Acute changes
Neurological manifestations of mild TBI
TBI is classified along a continuum with mild, moderate, and severe categories.6 The 
pathophysiology of mild TBI remains poorly understood due to the absence of diagnosis 
using standard clinical imaging, or other symptomatic measurements.7 Symptoms are on a 
spectrum, and range from momentary disorientation to slight amnesia.8 The limited range of 
symptom presentation makes it difficult to localize focal brain lesions.
The American Congress of Rehabilitation Medicine (ACRM, 1993) defines mild TBI as an 
alteration of brain function caused by external forces with one or more of the following: loss 
of consciousness (LOC) lasting 0–30 minutes, amnesia <24 hours, focal neurologic deficits 
that may or may not be transient, and mental state alteration at the time of the accident.9 In 
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2004, the World Health Organization (WHO) redefined the criteria for mild TBI. They 
specified that the GCS score should be 13–15 at time of presentation, instead of limiting it to 
a score of >13 within 30 minutes.10 In all likelihood though, these guidelines do not reflect 
the modern viewpoints of TBI, in which the spectrum of injury has now increased to 
recognize not only concussive injury, but also subconcussive injury as well as frequency of 
exposure.11 A diagram of clinically defined injury severity in regards to LOC and the GCS 
has been portrayed in Fig. 1.
Acute and subacute symptoms
At least 80% of patients report one or more symptoms in the acute period after mild TBI. Up 
to 20% of athletes suspected of having a concussion are asymptomatic, indicating possible 
subconcussive injuries.12,13 Patients typically present with cognitive, physical, and 
behavioral signs and symptoms. The most frequent symptoms include headache, dizziness, 
and memory impairment. LOC is not a requirement for the diagnosis of concussion; 
therefore, the primary diagnostic symptoms of mild TBI evaluate neurosensory 
performance.14 Dizziness has been reported as the most common symptom of mild TBI, 
closely followed by headache.15 Cognitive disorders, sleep disorders, and hearing disorders 
such as, tinnitus, hearing loss, and central auditory processing disorder are also common.16 
In a study of over 500 mild TBI patients, the authors concluded that neurosensory symptoms 
can persist for several months after injury, and can include blurry vision and personality 
changes.17 An overview of common symptoms that are evaluated after mild TBI have been 
highlighted in Fig. 2.
Concussion
Concussion has multiple definitions without a consensus. Concussion remains a clinical 
diagnosis that is subject to variability. Concussion is often referred to as the mildest end of 
the mild TBI spectrum. The American Academy of Neurology (AAN) divided concussion 
into three different grades to establish management guidelines for sports injuries. These 
guidelines include: Grade 1-no LOC, momentary confusion, mental status abnormalities <15 
minutes, Grade 2-no LOC, transient confusion, mental status abnormalities lasting 15 
minutes to 1 hour, and Grade 3-LOC, confusion, mental status abnormalities that may last 
more than 1 hour.18 The thresholds between grades are arbitrary, and in light of these 
findings, the AAN released updated guidelines that focus more on the management of 
concussion.19 Management is dependent upon salient features from a historical and physical 
exam. No single test score can be the basis of a concussion diagnosis. The success of 
concussion care is dictated by acute symptom treatment and timely recovery.20
Chronic changes
Common symptoms
Patients exposed to repetitive mild TBI can develop chronic symptoms that are both 
functional and behavioral in nature. Franke and colleagues have shown that mild TBI 
induces slowing of EEG oscillations.21 This slowing may account for the earlier onset of 
mild cognitive impairment in this population.22 Furthermore, patients frequently present 
with deficits in executive function.23 While the above two symptoms are the most 
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debilitating, other common symptoms that are chronic and frequent following mild TBI 
include headache, fatigue, and irritability.24 Several of these symptoms have been linked to 
sleep disturbance that is frequently reported after repetitive mild TBIs.25 In rare situations, 
repetitive mild TBI can also lead to the onset of post-traumatic epilepsy. The etiology 
however is not fully understood.26 The persistence of symptoms can negatively affect the 
patient and prevent a return to work.27 We address how supplements and alternative 
therapies target some of these symptoms later in this review.
Dementia pugilistica and chronic symptoms
Athletes exposed to repetitive concussions during contact sports are at an increased risk for 
the development of cognitive deficits.28 This has been historically characterized in boxers’ 
who have histories of multiple bouts of head injury. Dementia Pugilistica was the first 
neurotrauma-related neurodegenerative disease described. It was first found in boxers’ who 
received repetitive punches to the head. Symptoms developed months to years after 
repetitive injury and were correlated to distinct pathological changes within the brain. 
Parkinsonism was also linked with dementia pugilistica in select cases. When tremor and 
rigidity dominate the clinical picture, the term ‘pugilistic parkinsonism’ is applied.29 
Chronic onset dementia pugilistica has been proposed in the past decade. This phenotype 
has been associated with a clinical history of aggressive and violent behavior, but warrants 
further investigation.30
In other sports, some of the deficits following repetitive neurotrauma include mood and 
behavioral changes. Retired National Football League (NFL) players, for example, have a 
threefold increased risk of developing depression after retirement if they had received 
multiple concussions throughout their career.31 A nine year clinical follow-up study showed 
a link between concussions and depression.32 Further neuropsychological examination of 
former NFL players validated this relationship between a self-reported concussion history 
and depression.33 In addition to depression, retired NFL players who sustained three or more 
concussions reported increased cognitive symptoms, such as memory consolidation 
deficits.34 Additional studies also found cognitive deficits in retired NFL athletes after 
neuropsychological examination.35 Cognitive impairments have also been correlated with 
the incidence and frequency of head impacts in young football players equipped with 
helmet-mounted accelerometers.36 Moreover, after pathological examination of brains from 
the Mayo clinic, of the brains exhibiting signs of chronic disease, 33% of patients had 
participated in contact sports.37 Although these studies supply important information, the 
studies are retrospective in nature, and require further prospective investigation to eliminate 
recall bias.
CTE: Clinical manifestations
The symptoms of CTE are insidious Fig. 3. At first, patients have disturbances associated 
with poor attention or concentration, which can trigger impulsivity. The initial symptoms 
usually appear around ages 35–45 years.38 They are followed by headaches, short-term 
memory difficulty and aggressive tendencies. Typically a long latency (8 years) exists 
between head injury and the development of CTE symptoms.39 Recent evidence suggests 
that some athletes develop symptoms of CTE while actively playing contact sports.40 At this 
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point, it is unclear whether symptoms denote prolonged PCS or the early manifestations of 
CTE.29 A case series reported that headache is a persistent and early symptom in nearly 50% 
of patients who develop a comprehensive description of clinical CTE.41 They also listed a 
broad range of clinical manifestations, in the domains of cognition, behavioral changes, and 
mood disturbances that warrant further investigation with prospective studies.
Because CTE is still a post-mortem diagnosis characterized by neurofibrillary tangles, these 
symptom classifications are still being debated. Due to the subtle clinical features common 
among the general population, it is challenging to differentiate CTE from other diseases 
without pathologic confirmation.20 Mez and colleagues evaluated available case series and 
grouped CTE symptoms into stages: Stage 1, attention loss and headache, Stage 2 
depression and short-term memory loss, Stage 3 cognitive impairment, and Stage 4 poor 
verbal skill and aggression.42 Stage 1 symptoms are likely ‘preclinical’ because the 
pathology is unlikely to cause long-term clinical manifestations at this point in the disease 
process.43
Secondary effects of TBI
The primary effects of TBI are currently untreatable; however, secondary injury effects, 
which include cellular stress, immunotoxicity, oxidative stress, and inflammation can be 
treated.44 At the cellular level, TBI can deplete intracellular energy stores and cause 
subsequent failure of ATP-dependent ion pumps.45 Pump failure can trigger neuronal 
membrane depolarization and increase glutamate release.44 Augmented extracellular 
glutamate levels can activate glutamate receptors, which are known to allow positively 
charged ions into the cell.45 An excessive influx of positive ions can trigger 
immunoexcitotoxicity and neuronal cell death.46 Neuronal cells activate intrinsic 
mechanisms that produce and conserve energy to avoid imminent cell death. Mechanisms 
include catabolism, autophagy, phospholipase activation, and the organelle stress 
response.44,47
Reactive oxygen species
As mentioned before, augmented glutamate levels can activate catabolic processes that are 
known to increase intracellular reactive oxygen species (ROS). ROS production can lead to 
membrane lipid oxidation, an additional secondary injury mechanism observed in TBI.44 
Therefore, compounds that can decrease the amount of ROS have a potential role in TBI 
therapy. ROS damage can also be reduced through implementation of free radical 
scavengers.48 Many antioxidants can donate electrons to free radicals in order to neutralize 
toxic effects. Glutathione and edaravone are free radical scavengers that are also potent 
antioxidants that provide beneficial peripheral effects. Roth and colleagues delivered 
glutathione, directly into the brain through a thinned skull and observed reduced ROS levels 
and an amelioration of brain injury markers.49 Edaravone reduced oxidative stress and 
increased neuronal survival in a weight-drop model of TBI.50 The use of free radical 
scavengers is an intriguing strategy for reducing TBI-induced oxidative stress Fig. 4. This 
strategy was also effective in other neural injury models such as ischemic stroke; however, 
the short half-lives of these compounds limits the brain bioavailability.
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Due to a longer half-life, lipid peroxidase inhibitors have been shown to be more 
neuroprotective than direct free radical scavengers.48 Found endogenously in the brain, 
lipoic acid (LPA) is a potent antioxidant that can reduce lipid peroxidation. LPA has been 
shown to decrease neuronal cell death when administered after TBI.51 LPA can also increase 
the activity of antioxidants such as superoxide dismutase and glutathione. However, as 
mentioned before these antioxidants have a very short half-life and are only effective after 
mild bouts of oxidative stress.48 Another way to inhibit lipid peroxidation is to chelate free 
iron. The iron chelator, deferoxamine, has shown improved outcome in animal models of 
TBI.48 Iron chelation can prevent the catalyzation of lipid breakdown and lipid peroxide 
formation in the brain.48
Nutrition and supplements
Nutrition and supplementation may be a viable treatment option for the secondary effects of 
TBI. While evidence-based guidelines for nutrition are suggested for thoracic trauma, few 
studies have provided specific recommendations for TBI. In 2011 a consensus was 
established that advanced nutritional planning should be started 24–48 hours after TBI.52 A 
multi-center cohort study published in 2012 found that patients receiving enteral nutrition 
within 48 hours of injury had better survival rates and improved GCS scores.53 Other studies 
recommend an increased caloric intake, with the addition of 1–1.5 g/kg of protein, for two 
weeks post-injury.54
Specific nutrients can be chosen for supplementation based on their putative roles in the 
mechanisms of brain injury. The primary effects of TBI cause neuronal membrane 
dysfunction and vasculature damage which can lead to ischemia.55 Ischemia can alter 
cellular metabolism and result in ROS production, which can cause further damage to 
neuronal membranes.56 When neuronal membranes are damaged, intracellular Ca2+ 
homeostasis is perturbed, which can cause ER stress and potentially apoptosis. Nutritional 
targets may reduce the secondary effects of TBI, such as inflammation, ROS production, and 
neuronal cell death. Commonly used dietary supplements for TBI are discussed below.
Vitamins and minerals
Vitamin and mineral supplementation have been shown to improve outcome in pre-clinical 
models of mild TBI.46 Vitamin D deficient rodents displayed worsened outcome after TBI.57 
The combination therapy of Vitamin D (1μg/kg) and progesterone (16 mg/kg) was shown to 
reduce markers of inflammation and neuronal cell death in a model of TBI.58 Progesterone 
has even shown neuroprotective effects in patients exposed to TBI.59 Another vitamin to 
consider for TBI clinical trial therapy is Vitamin E. Interestingly, Vitamin E supplementation 
(2 IU/g) improved cognition following repetitive concussive brain injury in mice.60 Vitamin 
E also reduced oxidative stress and improved learning and memory in a fluid percussion 
model of TBI.61
The water-soluble vitamin nicotinamide improved recovery in rodents following mild TBI 
when given with progesterone.62 Continuous infusion of nicotinamide (150 mg/kg per day) 
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provided the most robust neuroprotection following mild TBI in rodents.63 This sustained 
administration paradigm has been linked to improved functional recovery.64 In contrast, folic 
acid administration for TBI therapy has been controversial. Naim and colleagues showed 
that folic acid can increase functional recovery following mild TBI in piglets.65 Vonder Haar 
and colleagues however showed no treatment effect with folic acid administration in rodents 
following mild TBI.66 This may indicate that vitamin supplementation may have species-
specific effects. Vitamins have not yet been used in clinical trials for TBI. They may be best 
used as adjuvant agents to improve the effectiveness of promising therapeutics.46
Zinc, a cofactor of superoxide dismutase, has shown promise as a supplement to TBI 
therapy. In addition to oxidative stress reduction, zinc was also shown to reduce 
inflammation, apoptosis, and autophagy in pre-clinical models of neural injury.54 Zinc 
supplementation (180 ppm) for four weeks was also shown to decrease depression and 
anxiety in rats following TBI.67 Hypozincemia has been linked to depression and could be 
correlated to the incidence of depression after TBI.68 Zinc serum levels are reduced in mild 
TBI patients, possibly due to the hypoalbuminemia that can develop after injury, which can 
disrupt serum zinc availability.69 This finding however has not yet been verified for mild 
TBI and warrants a double blind clinical trial. Introducing high levels of zinc into the diets 
of TBI patients may help to preserve brain tissue and reduce neuropsychiatric symptoms.
Magnesium is another mineral that has been shown to improve recovery following TBI in 
pre-clinical models.70 Furthermore, Wahls and colleagues found that magnesium was one of 
the four key nutrients that correlated with improved somatic scores when supplemented 
following mild TBI in humans.71 Magnesium is commonly depleted following TBI likely 
through interaction with transient receptor potential melastatin, which leads to neuronal cell 
death.72 Magnesium readily enters the brain following mild TBI in rodents, but has not been 
shown to significantly increase in the CNS when supplemented in humans. Sen and Gulati 
found that co-administration of magnesium with mannitol may increase brain bioavailability 
in humans.73 Further work is needed to determine if combined therapy might improve the 
efficacy of magnesium supplementation in humans following mild TBI.
Pharmaceutical supplements
The detrimental effects of neural injury can also be reduced with cyclooxygenase (COX) 
inhibition. TBI is proposed to activate COX2, which is known to induce chronic 
inflammation after neural injury. Indomethacin, a non-selective COX inhibitor, has been 
shown to improve neurological outcomes following sports-related concussion.74 The anti-
inflammatory drug, carprofen, also improved TBI outcome by reducing TBI lesion size and 
increasing neurogenesis in rodents.75 Used only for investigational study, Rolipram, an 
antidepressant drug, is a selective phosphodiesterase-4 inhibitor that was shown to be 
neuroprotective in a mouse model of TBI.76 Rolipram was shown to improve synaptic 
plasticity after TBI, and even improve cognitive performance.77 These compounds have 
been shown to be neuroprotective in a variety of pre-clinical TBI models; however, no 
compounds have survived the rigor of clinical trials to become viable treatments. Proposed 
reasons are due to the heterogeneity of TBI. Ongoing trials have grouped patients into more 
distinct categories, and may found better results for select subgroups of TBI.
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Docosahexaenoic acid (DHA) is an omega-3 fatty acid primarily stored in neuronal cell 
phospholipids.46 Phospholipase activation can release free fatty acids into the cell to 
promote cellular homeostasis. DHA release has been shown to counteract excessive 
glutamate activity following mild TBI in rodents Fig. 4.78 DHA has also been shown to 
promote synapse formation and upregulate glutamate receptor expression; thereby reducing 
excitotoxicity.79 A beneficial prophylaxis for patients suffering from TBI may be DHA. 
Studies show that DHA supplementation improved cognition and reduced markers of 
neuronal cell death in an impact-acceleration TBI model.80 DHA treatment reduced aberrant 
protein aggregation and improved neurobehavioral outcome in a controlled cortical impact 
model of TBI.81 Moreover, endogenous DHA depletion prior to TBI caused worsened 
outcomes in cognitive and motor function.79 A parent compound of DHA, α-linolenic acid, 
has also been shown to have neuroprotective effects preclinically.82 The results of DHA 
supplementation in an animal model of TBI, suggested both pre-injury neuroprotection and 
post-injury reduction of beta-amyloid precursor protein.83 DHA may protect neurons by 
decreasing nitric oxide levels and subsequent ROS.84 DHA may also indirectly decrease 
ROS by increasing activity of glutathione peroxidase and glutathione reductase.84 DHA 
supplementation post-TBI can reduce protein oxidation and restore neuronal cell 
homeostasis in order to manage the enduring effects of the injury.85 DHA is a safe and easily 
accessible compound that could benefit people exposed to a neurotraumatic event. To 
successfully implement DHA in a clinical trial, it will be necessary to perform human pilot 
studies in order to determine the most effective dosing strategy.
Dietary supplements in pre-clinical models of TBI
Dietary supplements have been shown to improve outcome in models of experimental TBI; 
however, clinical trials using supplements have continued to fail. New supplements that 
show promise in experimental TBI models include: curcumin, sulforaphane, and resveratrol.
Curcumin normalized brain-derived neurotrophic factor levels, and improved motor and 
learning performance in animals exposed to TBI.86 Sulforaphane was shown to improve 
blood–brain barrier integrity,87 reduce cerebral edema and improve cognition in a rodent 
model of TBI.88 Resveratrol has been shown to reduce ROS, suppress excitotoxicity, and 
reduce inflammation in a controlled cortical impact model of TBI.89 Resveratrol also 
reduced lipid peroxidation, decreased TBI lesion size, and specifically protected astrocytes 
after experimental TBI.90 Lipoic acid stabilized neuronal plasma membranes, prevented 
NADPH oxidative stress, and improved behavior following mild TBI in rats.91 Ansari and 
colleagues showed that different types of antioxidants are depleted at various time points 
following mild TBI.92 Therefore, targeting mild TBI with different types of antioxidants 
may be a viable approach to treatment. These supplements have not been used in clinical 
trials for TBI. A combination of supplementation and pharmaceutical intervention should be 
the focus for clinical trial paradigms moving forward.
Supplements in clinical trials for TBI
New efforts are being made to improve clinical trials for the treatment of TBI. TBI patients 
have shown decreased melatonin concentrations, likely contributing to their sleep 
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disturbances.93 Melatonin is currently in Phase I clinical trials for youth TBI to assess 
GABAergic effects.94 Melatonin is promising in that it is endogenous and has been shown to 
be decreased even after mild TBI. Choline administration, enhanced cerebral blood flow in 
TBI patients;95 however, in a follow-up randomized, double-blinded, multi-center COBRIT 
trial, choline was shown to have no difference from placebo.96 Another clinical trial 
compound for TBI is an extract, known as enzogenol. Enzogenol (1000 mg/kg) was shown 
to improve cognition when administered to TBI patients in a randomized, controlled study.97 
It had no adverse effects and the promising pilot data warrants verification with a larger 
more definitive clinical trial. Due to the complex pathophysiology of TBI, a combination of 
nutrients and supplements may be essential for optimal treatment. The overall goal is to 
implement new supplements such as, Melatonin, Choline, and Enzogenol into 
pharmaceutical-based clinical trials for TBI. A combined approach of supplement and 
pharmaceutical treatment will likely be the most beneficial.
Nutrition
While the hope is that optimal nutrition can improve TBI outcome, it is intuitive to think that 
malnutrition can adversely affect outcome. In a retrospective study, body mass index less 
than 18.5 was associated with higher mortality in intensive care patients and longer hospital 
stays.98 In a mild TBI clinic study, patients were surveyed about their nutritional intake. 
None of the patients met the recommended daily allowance for all 14 specified nutrients, and 
worsened outcome scores were linked with the lowest nutrient intake compared to those who 
had the highest nutrient intake.71 TBI patients who were malnourished at the time of 
admission exhibited lower albumin and prealbumin levels and were correlated to have poor 
neurological scores.99 The above evidence suggests that implementing nutritional 
supplementation can improve outcomes following mild TBI.
Alternative therapy
In addition to ‘natural products’ (e.g., herbal remedies, vitamins), alternative therapies can 
be used for TBI, which include: acupuncture, acupressure, mind-body practices, and music 
therapy Fig. 5.
Acupuncture
Acupuncture involves the stimulation of specific ‘acu-points’, or meridian points, on the skin 
to normalize aberrant flow of Qi by the insertion of fine needles either by hand or through 
electrical stimulation.100
A Cochrane systematic review on the safety and efficacy of acupuncture in the acute 
management and/or rehabilitation of individuals with TBI had identified four randomized 
controlled trials studies with a total of 294 participants.100 All trials had two groups to 
compare needle acupuncture to electrical acupuncture. After acute TBI, acupuncture 
improved overall functional outcome on the GCS,101 the Glasgow Outcome Score 
(GOS),101,102 and motor and speech functions.101 In the rehabilitation phase after TBI, 
acupuncture improved overall functional outcome on the Barthel Index,103 Modified Barthel 
Index,104 motor function on the Fugl-Meyer Assessment,104 and muscle strength grading.103 
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However, though all four studies were described as randomized, they were deemed by the 
review authors to carry a high risk of bias. Randomization procedures were not described, 
blinding information was not available, no placebo or sham control group was used, and 
variation in the acupuncture treatments existed among the different participants. 
Consequently, the authors noted that the current evidence in this review were greatly 
insufficient to support recommendations for acupuncture as a standard procedure for TBI in 
clinical practice. Moreover, no adverse effects of acupuncture were reported in any of the 
clinical trials reviewed. Although serious adverse effects are rare, the incidence of minor 
adverse events may be considerable.105 In the few studies that have reported adverse effects, 
38% of all patients experienced some bleeding,106 28% reported at least one adverse 
event,107 and 45% reported an aggravation of pain.108 The potential side effects of 
acupuncture in the context of TBI treatment and rehabilitation remain unclear and 
understudied.
In a recent population-based investigation from Taiwan, TBI patients who underwent 
acupuncture treatment were found to require less medical care within the first year.109 In a 
follow-up study, TBI patients with acupuncture treatment were found to have a lower 
incidence of stroke compared to patients not receiving acupuncture treatment.110 Despite 
having a large sample size, the database lacked detailed patient information on lifestyle, 
physical, psychiatric, and laboratory examinations.110 Additionally, the mode of acupuncture 
treatment for patients with TBI varied with Traditional Chinese Medical physicians.110 In 
another study, involving 24 adult TBI survivors randomized to acupuncture of control arms, 
the authors demonstrated that acupuncture had beneficial effects on perception of sleep, or 
sleep quality.111 The acupuncture group also showed improvements on measures of 
cognition and depression not observed in the control group.111 Unfortunately, this study had 
a risk of bias comparable to the studies identified in the Cochrane review, including failure 
to report randomization sequence and failure to blind observers. Clinical trials with lower 
risk of bias and investigations into the specific acupuncture points are necessary to better 
determine the efficacy and safety of acupuncture in individuals with TBI.
Acupressure
Acupressure is another form of Traditional Chinese Medicine that involves the application of 
pressure to specific ‘acupoints’ to affect the flow of Qi. Distinct from acupuncture, it is non-
invasive, using hands, fingers, or thumbs instead of needles.
In a randomized, placebo-controlled, single-blind study, the authors demonstrate enhanced 
working memory among TBI patients after acupressure treatments.112 Forty-two adults with 
mild TBI were randomized to receive active acupressure treatment (eight treatments over 
four weeks), or sham acupressure treatment.112 Cognitive function (working memory, 
attention, motor speed, and spatial problem solving) was assessed using a battery of 
neuropsychological tests. Neurophysiological measures were also added to delineate 
mechanisms underlying potential cognitive change associated with the treatment. To do so, 
event-related potentials were recorded during performance on specific cognitive tasks,112 as 
previous studies have shown that even mild TBI affects the amplitude and latency of these 
recordings.113 Compared with those in the placebo group, those in the active acupressure 
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group demonstrated a reduction in P300 latency (increased speed with which memory 
operations occur) and amplitude (the degree of memory engagement).112 The active-
treatment group also showed improvements in attention as compared with the placebo group 
on the Stroop task and Digit Span task.112 There were no significant between-group 
differences on other measures of neuropsychological function, or measures of anxiety, 
depression, or loneliness.112 Strengths of this study included a strong effect size (Cohen’s d 
= 0.68 for digit span involvement) and the use of multiple behavioral and physiological 
measures of treatment-associated change.113 Limitations include the lack of long-term 
follow-up to assess for the enduring nature of acupuncture treatment effects. Adverse effects 
were also not reported. In addition, individuals with mild TBI were identified via the Brain 
Injury Screening Questionnaire, which has good reliability and validity, but is still a self-
report measure to detect TBI.114
Mind-body practices
Mind-body practice uses the power of thoughts and emotions to influence physical health, 
and vice-versa. Some examples of mind-body medicine practices are meditation, hypnosis, 
tai chi, qi gong, and yoga. Preliminary studies show that these interventions can enhance 
parasympathetic tone, heart rate variability, neuroplasticity, EEG synchrony, long-term 
potentiation, and oxygenation in mental health care.115
Yoga, in particular, is a mind-body practice with origins in ancient Indian philosophy that 
typically combines physical postures, breathing techniques, and meditation or relaxation. 
However, there were only ten individuals who attended weekly yoga classes and four 
individuals in the no-treatment group. The small sample sizes precluded the analysis of 
between-group analyses. In another yoga study, Schmid et al. demonstrated that yoga may 
be feasibly delivered in a one-to-one setting and improve multiple aspects of physical 
function in individuals with chronic TBI.116 Only three patients were involved in the study, 
and assessments were taken before and after the 8-week yoga intervention.116 Further 
investigation of yoga for the treatment of TBI is warranted.
Tai Chi and qi gong also involves certain postures and gentle movements with mental focus, 
breathing and relaxation. They are rooted in the Chinese philosophical tradition of Taoism. 
In contrast to qi gong, ta chi movements, if practiced quickly, can be a form of combat or 
self-defense. In a study involving 18 participants, with nine each assigned to a control 
(waiting list) or Tai Chi group, Gemmell and Leathem found Tai Chi to reduce confusion, 
tension and fear among TBI patients.117 There was however no between-group differences 
in mood, self-esteem, or mental well-being after three weeks of completing the Tai Chi 
course.117 Qi gong, however, improved mood and self-esteem among individuals with 
TBI.118 In this study, 20 individuals were randomly assigned to receive the qi gong 
intervention (n = 10), or to a non-exercise leisure activity control group (n = 10).118 After 
eight weeks, self-esteem and mood were improved in the qi gong group compared to 
controls.118 Future large-scale randomized control trials are needed to assess the therapeutic 
potential of Tai Chi and qi gong for the management of TBI.
Mindfulness-based cognitive therapy (MBCT) incorporates the elements of cognitive-
behavioral therapy. Mindfulness-based stress reduction (MBST) identifies our thoughts 
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without passing judgment to those thoughts.119 Initially designed to aid in the prevention of 
relapse of depression, specifically in individuals with major depressive disorder, MBCT has 
since been applied to various neurological and psychiatric conditions. To demonstrate the 
efficacy of MBCT in the treatment of clinically diagnosed depression in TBI patients, 
Bedard et al. recruited 23 participants for an 8-week study, with a 90-min MBCT session 
once a week.120 They found that MBCT significantly reduced depression symptoms on all 
scales compared to baseline.120 Participants also indicated reduced pain intensity and 
increased energy levels.120 No significant effects were found on anxiety symptoms, pain 
frequency, and level of functioning.120 In a pilot study, Berdard et al. showed MBST 
delivered to TBI patients produced a better quality of life and reduced depression 
symptoms.121 Interestingly, in a one-year follow-up study, Bedard et al. found MBST to 
offer sustained effects on several key outcome measures, including depression symptoms.122 
However, this finding has to be interpreted with caution as there was no control group, and 
three of the ten original MBST group participants were lost to follow-up. Moreover, whether 
or not the participants continued to use the skills they acquired was not assessed.
Music therapy
Music therapy is a therapeutic intervention to address the emotional, physical, and spiritual 
needs of an individual. Music therapy can be broadly categorized as ‘active’, in which 
people re-create, improvise, or compose music, and ‘receptive’, in which they listen to 
music.122 Music therapy treatment involves selecting from a range of music-based 
interventions, using both music and the therapist–patient relationship as agents of change.123
A recent Cochrane systematic review of music therapy as a rehabilitation intervention for 
people with acquired brain injury (e.g., stroke and TBI) included seven studies with a total 
of 184 participants.123 Interventions included rhythmic auditory stimulation (RAS)124–126 
electronic music making,127 rhythmic-melodic voice training128, and listening to pre-
recorded songs 129,130 or live music.129 In stroke patients, RAS may be beneficial for 
improving gait velocity, cadence, stride length, and stride symmetry.123 While one study 
observed a significant improvement of upper extremity function during RAS,124 music 
therapy was found to reduce agitation, and improve orientation levels compared to no 
music.129 As most of these studies focused on stroke patients, further studies implementing 
music therapy for TBI patients are needed.
Overall, the evidence presented thus far for the beneficial effects of alternative therapies for 
TBI patients is insufficient. Most of the studies reviewed have a high risk of bias (e.g., 
failure to blind, failure to report randomization procedures, and failure to use a placebo or 
sham control group) and small sample sizes. Moreover, safety data on many of the 
interventions were not reported at all. Albeit encouraging, additional rigorous and 
methodically sound randomized control trials are needed before recommendations can be 
made for clinical practice.
Conclusion
The chronic neurological deficits of TBI are complex and clinical treatments are limited. In 
this review, we highlighted TBI diagnosis, pharmaceutical targets of TBI, supplementation 
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to traditional treatment for TBI, and the approach of alternative medicine. Ongoing failure of 
clinical trials for TBI treatment has questioned the direction of therapy. Nutritional 
Supplementation, including vitamins, has emerged as a promising therapeutic option for 
TBI. No class I evidence is available for the effectiveness of supplementation; however, 
several class III studies have shown the minerals magnesium and zinc to be most effective at 
improving both pre-clinical and clinical TBI outcome. The literature is mixed on 
supplements such as coline and melatonin. There is class IIC evidence that enzogenol is 
effective. Alternative therapies may also help to treat neuropsychiatric symptoms associated 
with TBI, however, definitive clinical trial evidence is lacking. Going forward it will be 
important to learn how supplementation and alternative therapies can be incorporated with 
clinical practice to improve outcomes for TBI patients. Combination therapies of 
supplementation and pharmaceutical agents are likely to yield the best results. Furthermore, 
the treatment regimens need to be tailored more specifically to the type of TBI based on 
primary injury and severity. Several clinical trials have failed because heterogeneous TBI 
patients with a wide range of injury severities were grouped together in the same studies. 
Specifically targeting key biochemical mechanisms with different agents at the appropriate 
time points will likely lead to more successful clinical trials going forward.
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Schematic showing the progression of injury severity in correlation to loss of consciousness, 
diffuse axonal injury, and the Glasgow Coma Scale score.
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Symptoms associated with acute phase and late phase post-traumatic disorder.
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Symptoms associated with chronic traumatic encephalopathy.
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Key supplements under investigation and the proposed mechanisms of action.
Lucke-Wold et al. Page 24














Alternative therapy approaches for the treatment of TBI.
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